Jazz Pharmaceuticals plc (JAZZ)
Valor JustoFundamental
70
Precio
$233.55
Capitalización Bursátil
$15.03B
Parte 1 · Cuánto vale la empresa
Resumen
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance y Liquidez
Ingresos
$4.60B
Últimos 12 meses (hasta 30/6/2026)
Beneficio Neto
$941M
Últimos 12 meses (hasta 30/6/2026)
Flujo de Caja Libre
$1.30B
Patrimonio Neto Total
$4.32B
Pasivo Total
$7.34B
Ratio de Liquidez
1.78
Cobertura de Intereses
-
Deuda/EBITDA
-
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$257.79
Precio Actual
$233.55
Margen de Seguridad
+9.4%
Rango de Valor Justo
$167.57 - $348.02
Dispersión entre los métodos de valoración utilizados, no un intervalo de confianza calibrado estadísticamente.
Métodos de Estimación
Métricas de Valoración
Ratio P/E
15.83
ROE
-8.2%
Ratio P/B
3.13
P/FCF
9.44
Margen Bruto
-
ROIC
8.0%
Radar de Rentabilidad
Creación de Valor (Ventaja Competitiva)
ROIC
8.0%
WACC
6.2%
ROIC − WACC
+1.8 pp
El ROIC supera el coste del capital: la empresa está creando valor para los accionistas.
Criterios de Análisis Fundamental
Superado (17)
- Price CAGR 7.98%
- ROIC 8.0%
- P/FCF 9.44
- Debt/Equity ratio
- Operating Margin 19.5%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Return on Tangible Assets
- ROE 21.4%
- Revenue Growth 5Y 12.5%
- Analyst Consensus 92% Buy
- Earnings Surprise avg 15.3%
- Earnings Quality (OCF/NI) 1.77
- Share Dilution -5.8%
- Net Margin Trend 20.4% vs -9.9%
- Piotroski F-Score 5/9
Fallido (5)
- EPS shows upward trend
- P/B Ratio 3.13
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
No disponible (5)
- Gross Margin NaN%
- Dividend Payout NaN%
- Interest Coverage
- Debt/EBITDA
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Señales mixtas: algunas áreas requieren atención
Calidad de los Beneficios
Alta calidad: beneficios respaldados por efectivo
Dilución de Acciones
Recomprando acciones. Favorable para el accionista
Participaciones institucionales
No hay declaraciones institucionales para esta empresa.
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Mr. Bruce C. Cozadd | Co-Founder & Chairman | 61 |
| Ms. Renee D. Gala | President, CEO & Director | 53 |
| Mr. Philip L. Johnson | Executive VP & CFO | 61 |
| Ms. Neena M. Patil J.D. | Executive VP & Chief Legal Officer | 50 |
| Dr. Robert Iannone M.D. | Executive VP, Chief Medical Officer and Global Head of Research & Development | 58 |
| Ms. Samantha Pearce | Executive VP & Chief Commercial Officer | 59 |
| Ms. Patricia Carr | Senior VP & Chief Accounting Officer | 54 |
| Mr. John D. Bluth | Head of Investor Relations | 52 |
| Ms. Heidi Manna | Executive VP & Chief People Officer | 54 |
| Dr. Jed Black M.D. | Senior Vice President of Sleep & CNS Medicine | - |
Riesgo de Auditoría
8
Riesgo del Consejo
4
Riesgo de Compensación
5
Riesgo de Derechos del Accionista
3
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Documentos
- Ver documento
Informe anual (10-K)
Un resumen anual del negocio, los resultados financieros y los riesgos de la empresa.
Presentado el 2026-02-24
- Ver documento
Informe trimestral (10-Q)
Una actualización del desempeño financiero de los últimos tres meses.
Presentado el 2026-08-03
- Ver documento
Informe de hecho relevante (8-K)
Un aviso sobre un hecho relevante, como un cambio de dirección o un anuncio importante.
Presentado el 2026-09-23
via SEC EDGAR
Historial de Resultados
via SEC EDGAR
Latest News
Recent headlines for JAZZ, sourced from Markets Gazette.
- 6/17/2026POSITIVEJazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaboration
Jazz Pharmaceuticals has entered into a strategic collaboration with AbCellera to discover and develop novel cancer therapies. This partnership aims to leverage AbCellera's AI-powered antibody discovery platform to identify potential drug candidates for challenging oncology targets. Despite a recent setback in a Zepzelca trial, this move signals Jazz's commitment to strengthening its oncology pipeline. Analysts remain optimistic, maintaining positive price targets, suggesting that this collaboration could be a significant catalyst for future growth and value creation for shareholders.
via Markets Gazette